Berubicin hydrochloride
Based on 1 Customer Validation
Berubicin (RTA 744) hydrochloride is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin hydrochloride inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin hydrochloride exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin hydrochloride can be used in the study of tumors related to the nervous system.
For research use only. We do not sell to patients.
- Purity: 95.08%
- CAS No.: 293736-67-1
- Formula: C34H36ClNO11
- Molecular Weight:670.10
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
Berubicin (0.1-10 μM, 0-5 d) hydrochloride is more effective than Doxorubicin (Dox) in inhibiting SH-SY5Y cell growth[2].
Berubicin (0-10 μM, 0-48 h) hydrochloride induces apoptosis at the lower drug concentrations through caspase-9 and -3-dependent pathways and activating NF-κB, while other mechanisms of cell death may predominate at higher concentrations in SH-SY5Y cells[2].
Berubicin (0-100 μM, 24 h) hydrochloride inhibits three AML cell lines K562, KBM-3, OCIM2 and KBM-5 cells with IC50s of 0.18, < 0.05, < 0.05 μg/mL and 0.5 μM, and induces cell apoptosis in cultured human acute lymphoblastic leukemia (ALL) CEM cells at 0.05 μM[3][4].
Berubicin (0-10 μM, 0-8 h) hydrochloride is more active than Dox in inhibiting DNA synthesis (IC50 = 0.2 μM), activating NF-κB and degradation of IkBα of KBM-5 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y cells
-
Concentration:0.05, 0.5 and 5 μM
-
Incubation Time:48 h
-
Result:\Induced significantly higher apoptosis at 500 nM than Dox, but higher concentrations of the drug reduced the apoptosis-inducing effect.
-
Cell Line:SH-SY5Y cells
-
Concentration:0, 0.1, 1.0 or 10 µM
-
Incubation Time:0, 0.5, 1, 2, 4, 6, 8, 12 or 24 h
-
Result:Observed a caspase-9 cleavage band as early as 0.5 h after drug treatment and accumulated to highest levels after 12 h, and caspase-3 cleavage was seen as early as 8 h.
Did not express caspase 8, and there was no increase or decrease in caspase 7 expression.
Significantly increased p53 levels, whereas Dox had no such effect and p21 expression increased with increased p53.
Significantly reduced mitochondrial AIF and nuclear AIF accumulation increases over time.
Showed 50 times more potent than Dox in activating NF-κB.
Downregulated the expression of IκBα, Bcl-w, Bcl-XL and cyclin D1.
-
Cell Line:KBM-5 cells
-
Concentration:0, 0.1, 1 and 10 µM
-
Incubation Time:0, 5, 10, 15, 30, 60, 120, 240, 480 min
-
Result:Was most active, reaching maximum activation in activating NF-kβ and degradation of IkBαat a 1 μM concentration, and Doxorubicin least active, reaching maximum at 50 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 293736-67-1
-
Appearance Solid
-
Molecular Weight 670.10
-
Formula C34H36ClNO11
-
Color Brown to red
-
SMILES
OC1=C2C([C@@]([H])(O[C@H]3C[C@H](N)[C@H](OCC4=CC=CC=C4)[C@H](C)O3)C[C@@](C(CO)=O)(O)C2)=C(O)C5=C1C(C6=CC=CC(OC)=C6C5=O)=O.Cl
-
Synonyms
RTA 744; WP 744; WP 769 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Faderl S, et al. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec;21(6A):3777-84. [Content Brief]
[2]. Wu J, Harris NL, Inge TH. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells. J Surg Res. 2004 Dec;122(2):231-9. [Content Brief]
[3]. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec;21(6A):3777-84. PMID: 11911247. [Content Brief]
[4]. Ashikawa K, et al. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol. 2004 Jan 15;67(2):353-64. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Berubicin hydrochloride Related Classifications
HY-14942A Related Classifications
Powered by Bioz